455 related articles for article (PubMed ID: 30676858)
1. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
Suda K; Murakami I; Katayama T; Tomizawa K; Osada H; Sekido Y; Maehara Y; Yatabe Y; Mitsudomi T
Clin Cancer Res; 2010 Nov; 16(22):5489-98. PubMed ID: 21062933
[TBL] [Abstract][Full Text] [Related]
4. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.
Cappuzzo F; Jänne PA; Skokan M; Finocchiaro G; Rossi E; Ligorio C; Zucali PA; Terracciano L; Toschi L; Roncalli M; Destro A; Incarbone M; Alloisio M; Santoro A; Varella-Garcia M
Ann Oncol; 2009 Feb; 20(2):298-304. PubMed ID: 18836087
[TBL] [Abstract][Full Text] [Related]
5. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
[TBL] [Abstract][Full Text] [Related]
6. Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer.
Park S; Langley E; Sun JM; Lockton S; Ahn JS; Jain A; Park K; Singh S; Kim P; Ahn MJ
Oncotarget; 2015 Oct; 6(31):30929-38. PubMed ID: 26439803
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy.
Dziadziuszko R; Holm B; Skov BG; Osterlind K; Sellers MV; Franklin WA; Bunn PA; Varella-Garcia M; Hirsch FR
Ann Oncol; 2007 Mar; 18(3):447-52. PubMed ID: 17082511
[TBL] [Abstract][Full Text] [Related]
8. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.
Cappuzzo F; Marchetti A; Skokan M; Rossi E; Gajapathy S; Felicioni L; Del Grammastro M; Sciarrotta MG; Buttitta F; Incarbone M; Toschi L; Finocchiaro G; Destro A; Terracciano L; Roncalli M; Alloisio M; Santoro A; Varella-Garcia M
J Clin Oncol; 2009 Apr; 27(10):1667-74. PubMed ID: 19255323
[TBL] [Abstract][Full Text] [Related]
9. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
[TBL] [Abstract][Full Text] [Related]
10. High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR.
Wang F; Fu S; Shao Q; Zhou YB; Zhang X; Zhang X; Xue C; Lin JG; Huang LX; Zhang L; Zhang WM; Shao JY
J Transl Med; 2013 Apr; 11():90. PubMed ID: 23557218
[TBL] [Abstract][Full Text] [Related]
11. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
12. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.
Kubo T; Yamamoto H; Lockwood WW; Valencia I; Soh J; Peyton M; Jida M; Otani H; Fujii T; Ouchida M; Takigawa N; Kiura K; Shimizu K; Date H; Minna JD; Varella-Garcia M; Lam WL; Gazdar AF; Toyooka S
Int J Cancer; 2009 Apr; 124(8):1778-84. PubMed ID: 19117057
[TBL] [Abstract][Full Text] [Related]
13. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
[TBL] [Abstract][Full Text] [Related]
14. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
Turke AB; Zejnullahu K; Wu YL; Song Y; Dias-Santagata D; Lifshits E; Toschi L; Rogers A; Mok T; Sequist L; Lindeman NI; Murphy C; Akhavanfard S; Yeap BY; Xiao Y; Capelletti M; Iafrate AJ; Lee C; Christensen JG; Engelman JA; Jänne PA
Cancer Cell; 2010 Jan; 17(1):77-88. PubMed ID: 20129249
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
Cappuzzo F; Hirsch FR; Rossi E; Bartolini S; Ceresoli GL; Bemis L; Haney J; Witta S; Danenberg K; Domenichini I; Ludovini V; Magrini E; Gregorc V; Doglioni C; Sidoni A; Tonato M; Franklin WA; Crino L; Bunn PA; Varella-Garcia M
J Natl Cancer Inst; 2005 May; 97(9):643-55. PubMed ID: 15870435
[TBL] [Abstract][Full Text] [Related]
16. Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis.
Zhao S; Ma Y; Liu L; Fang J; Ma H; Feng G; Xie B; Zeng S; Chang J; Ren J; Zhang Y; Xi N; Zhuang Y; Jiang Y; Zhang Q; Kang N; Zhang L; Zhao H
Lung Cancer; 2024 Feb; 188():107468. PubMed ID: 38181454
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.
McDermott U; Pusapati RV; Christensen JG; Gray NS; Settleman J
Cancer Res; 2010 Feb; 70(4):1625-34. PubMed ID: 20124471
[TBL] [Abstract][Full Text] [Related]
18. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
[TBL] [Abstract][Full Text] [Related]
19. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.
Benedettini E; Sholl LM; Peyton M; Reilly J; Ware C; Davis L; Vena N; Bailey D; Yeap BY; Fiorentino M; Ligon AH; Pan BS; Richon V; Minna JD; Gazdar AF; Draetta G; Bosari S; Chirieac LR; Lutterbach B; Loda M
Am J Pathol; 2010 Jul; 177(1):415-23. PubMed ID: 20489150
[TBL] [Abstract][Full Text] [Related]
20. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.
De Luca A; Normanno N
Curr Drug Targets; 2010 Jul; 11(7):851-64. PubMed ID: 20388064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
